A number of firms have modified their ratings and price targets on shares of Johnson & Johnson (NYSE: JNJ) recently:

  • 8/4/2017 – Johnson & Johnson had its “buy” rating reaffirmed by analysts at Credit Suisse Group.
  • 7/31/2017 – Johnson & Johnson was downgraded by analysts at Zacks Investment Research from a “buy” rating to a “hold” rating. According to Zacks, “J&J reported mixed Q2 results, beating on earnings but missing on sales. Sales in J&J’s domestic Pharma segment have decelerated this year as a number of key growth drivers like Remicade and Concerta are facing competition. However, J&J is optimistic that sales growth will accelerate in 2H17. We believe that new products including Xarelto, Stelara, Darzalex, and Imbruvica remain the key to growth.  Meanwhile, share buybacks and the restructuring initiative should provide bottom-line support. J&J is also making rapid progress with its pipeline and line extensions. The Actelion buy adds an attractive new therapeutic area – PAH. J&J’s shares have outperformed the large-cap pharma industry this year so far. However, headwinds like negative currency movement, generics, pricing pressure and soft global market conditions remain. Sluggish growth in the Consumer segment due to category slowdown is also a concern.”
  • 7/27/2017 – Johnson & Johnson was upgraded by analysts at Zacks Investment Research from a “hold” rating to a “buy” rating. They now have a $148.00 price target on the stock. According to Zacks, “J&J reported mixed Q2 results, beating on earnings but missing on sales. Sales in J&J’s domestic Pharma segment have decelerated this year as a number of key growth drivers like Remicade and Concerta are facing competition.  However, J&J is optimistic that sales growth will accelerate in 2H17. Though headwinds like negative currency movement, generics, pricing pressure and soft global market conditions remain, we believe that new products including Xarelto, Stelara, Darzalex, and Imbruvica remain the key to J&J’s growth. Meanwhile, share buybacks and the restructuring initiative should provide bottom-line support. J&J is also making rapid progress with its pipeline and line extensions. The Actelion buy adds an attractive new therapeutic area – PAH. J&J’s shares have outperformed the industry this year so far. However, sluggish growth in the Consumer segment due to category slowdown is a concern.”
  • 7/21/2017 – Johnson & Johnson was downgraded by analysts at BTIG Research from a “neutral” rating to a “sell” rating. They now have a $110.00 price target on the stock.
  • 7/21/2017 – Johnson & Johnson was downgraded by analysts at Atlantic Securities from a “neutral” rating to an “underweight” rating. They now have a $113.00 price target on the stock.
  • 7/21/2017 – Johnson & Johnson was downgraded by analysts at Alembic Global Advisors from a “neutral” rating to an “underweight” rating.
  • 7/21/2017 – Johnson & Johnson was downgraded by analysts at Zacks Investment Research from a “buy” rating to a “hold” rating. According to Zacks, “J&J reported mixed Q2 results, beating on earnings but missing on sales. Sales in J&J’s domestic Pharma segment have decelerated this year as a number of key growth drivers like Remicade and Concerta are facing competition. However, J&J is optimistic that sales growth will accelerate in 2H17. We believe that new products including Xarelto, Stelara, Darzalex, and Imbruvica remain the key to growth.  Meanwhile, share buybacks and the restructuring initiative should provide bottom-line support. J&J is also making rapid progress with its pipeline and line extensions. The Actelion buy adds an attractive new therapeutic area – PAH. J&J’s shares have outperformed the large-cap pharma industry this year so far. However, headwinds like negative currency movement, generics, pricing pressure and soft global market conditions remain. Sluggish growth in the Consumer segment due to category slowdown is also a concern.”
  • 7/20/2017 – Johnson & Johnson is now covered by analysts at Credit Suisse Group. They set an “outperform” rating and a $148.00 price target on the stock.
  • 7/19/2017 – Johnson & Johnson had its “buy” rating reaffirmed by analysts at UBS AG. They now have a $148.00 price target on the stock, up previously from $136.00.
  • 7/14/2017 – Johnson & Johnson had its “hold” rating reaffirmed by analysts at Jefferies Group LLC. They now have a $145.00 price target on the stock, up previously from $140.00.
  • 7/12/2017 – Johnson & Johnson was downgraded by analysts at BidaskClub from a “buy” rating to a “hold” rating.
  • 7/12/2017 – Johnson & Johnson had its “buy” rating reaffirmed by analysts at Royal Bank Of Canada. They now have a $138.00 price target on the stock.
  • 7/6/2017 – Johnson & Johnson had its “market perform” rating reaffirmed by analysts at Wells Fargo & Company. They now have a $135.00 price target on the stock, up previously from $132.00.
  • 7/5/2017 – Johnson & Johnson had its price target raised by analysts at Morgan Stanley from $135.00 to $140.00. They now have an “overweight” rating on the stock.
  • 7/1/2017 – Johnson & Johnson was downgraded by analysts at BidaskClub from a “strong-buy” rating to a “buy” rating.
  • 6/17/2017 – Johnson & Johnson was upgraded by analysts at BidaskClub from a “buy” rating to a “strong-buy” rating.
  • 6/16/2017 – Johnson & Johnson had its “hold” rating reaffirmed by analysts at Jefferies Group LLC. They now have a $140.00 price target on the stock.
  • 6/15/2017 – Johnson & Johnson had its “buy” rating reaffirmed by analysts at Royal Bank Of Canada. They now have a $128.00 price target on the stock.
  • 6/13/2017 – Johnson & Johnson had its “outperform” rating reaffirmed by analysts at Cowen and Company. They now have a $143.00 price target on the stock.

Shares of Johnson & Johnson (NYSE:JNJ) traded down 0.11% during midday trading on Thursday, reaching $133.09. The company’s stock had a trading volume of 5,607,853 shares. Johnson & Johnson has a 52-week low of $109.32 and a 52-week high of $137.08. The stock has a 50-day moving average price of $133.23 and a 200-day moving average price of $126.11. The stock has a market cap of $357.21 billion, a price-to-earnings ratio of 22.52 and a beta of 0.78.

Johnson & Johnson (NYSE:JNJ) last announced its earnings results on Tuesday, July 18th. The company reported $1.83 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.79 by $0.04. Johnson & Johnson had a return on equity of 26.76% and a net margin of 22.52%. The firm had revenue of $18.84 billion during the quarter, compared to analyst estimates of $18.94 billion. During the same quarter in the prior year, the company earned $1.74 EPS. The business’s revenue was up 1.9% compared to the same quarter last year. Equities research analysts anticipate that Johnson & Johnson will post $7.18 earnings per share for the current fiscal year.

The company also recently announced a quarterly dividend, which will be paid on Tuesday, September 12th. Stockholders of record on Tuesday, August 29th will be given a $0.84 dividend. This represents a $3.36 annualized dividend and a dividend yield of 2.52%. The ex-dividend date is Friday, August 25th. Johnson & Johnson’s dividend payout ratio is currently 56.76%.

In other news, VP Paulus Stoffels sold 102,692 shares of the stock in a transaction that occurred on Monday, July 24th. The stock was sold at an average price of $133.14, for a total value of $13,672,412.88. Following the completion of the transaction, the vice president now owns 230,342 shares of the company’s stock, valued at approximately $30,667,733.88. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, VP Dominic J. Caruso sold 82,591 shares of the stock in a transaction that occurred on Thursday, July 20th. The stock was sold at an average price of $136.72, for a total value of $11,291,841.52. Following the completion of the transaction, the vice president now directly owns 226,693 shares of the company’s stock, valued at approximately $30,993,466.96. The disclosure for this sale can be found here. 0.19% of the stock is currently owned by corporate insiders.

Johnson & Johnson is a holding company, which is engaged in the research and development, manufacture and sale of a range of products in the healthcare field. It operates through three segments: Consumer, Pharmaceutical and Medical Devices. Its primary focus is products related to human health and well-being.

Receive News & Ratings for Johnson & Johnson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson & Johnson and related companies with Analyst Ratings Network's FREE daily email newsletter.